A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration.

Trial Profile

A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2012

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Choroidal neovascularisation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 29 Feb 2012 Actual end date changed from Jun 2008 to Aug 2008 as reported by ClinicalTrials.gov.
    • 27 Apr 2011 Actual end date changed from Aug 2008 to Jun 2008 as reported by ClinicalTrials.gov.
    • 07 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top